Cilostazol Versus Aspirin for Primary Prevention of Atherosclerotic Events
NCT ID: NCT00886574
Last Updated: 2010-06-04
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE4
400 participants
INTERVENTIONAL
2009-04-30
2014-02-28
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Cilostazol and Aspirin in Stroke and TIA
NCT06522113
The Effect of Cilostazol Compared to Aspirin on Endothelial Function in Acute Cerebral Ischemia Patients
NCT03116269
Efficacy Study of Cilostazol and Aspirin on Cerebral Small Vessel Disease
NCT01932203
Cilostazol in Acute Ischemic Stroke Treatment (CAIST)
NCT00272454
Cilostazol vs. Aspirin in Acute Non-cardioembolic Stroke With Cerebral mIcrobleeds
NCT06530537
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
PREVENTION
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Aspirin
Aspirin 100 mg once a day
Aspirin
100 mg once a day
Cilostazol
Cilostazol 200 mg (50 mg 2T twice per day)
Cilostazol
Cilostazol 200 mg (50 mg 2T twice per day)
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Cilostazol
Cilostazol 200 mg (50 mg 2T twice per day)
Aspirin
100 mg once a day
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Hypertension (≧ 140/90 or anti-hypertensive therapy)
* Hypercholesterolemia (LDL-C \> 130 mg/dL or anti-hyperlipidemic therapy)
* TG \> 200 mg/dL
* Non proliferative retinopathy or macular edema
* Microalbuminuria or macroalbuminuria
* Smoker
2. Patients on no anti PLT drug history
3. Patients who are agree with this research
Exclusion Criteria
2. Macrovascular complication history
3. Uncontrolled hypertension, unstable angina history
4. Congestive heart failure
5. Bleeding tendency
6. Chronic liver disease (ALT \> 100 or AST \> 100) or Chronic renal disease creatinine \> 3.0 mg/dl)
7. Anemia (hemoglobin \< 10 mg/dl) or thrombocytopenia (platelet count less than 100,000/mm3)
8. Pregnant or lactation women
9. Plan to be revascularized in 4 weeks
10. Plan to go to surgery or invasive intervention in 4 weeks
11. Plan to need to admission for acute cardiovascular disease in 4 weeks
12. Contraindication of this medication
13. Other anti-PLT drug therapy
40 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Ajou University School of Medicine
OTHER
Kyunghee University Medical Center
OTHER
Korea University Guro Hospital
OTHER
Inha University Hospital
OTHER
Inje University
OTHER
Hallym University Medical Center
OTHER
Hanyang University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Department of Internal Medicine, Hanyang University
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Yongsoo Park, M.D. Ph.D
Role: PRINCIPAL_INVESTIGATOR
Department of Internal Medicine, Hanyang University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Inha University Hospital
Incheon, , South Korea
Hallym University Hospital
Pyungcheon, , South Korea
Hallym University Hospital
Seoul, , South Korea
Korea University Guro Hospital
Seoul, , South Korea
Kyung hee University Medical Center
Seoul, , South Korea
Ajou University Hospital
Suwon, , South Korea
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
HY-2009-11
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.